Table 8.
Relationships between IOP and Endothelial Cells or CCT Undergoing Intravitreal Bevacizumab Injection in patients excluding pseudophakic eyes (n = 37)
| Yb | ß1 (IOP) | p-valuea | ß2 (time) | p-valuea | ß3 (IOPa time) | p-valuea | Y-intercept |
|---|---|---|---|---|---|---|---|
| CD(cells/mm2) | −0.33 | 0.83 | 2.08 | 0.68 | −0.16 | 0.61 | 2695.86 |
| CV | 0.61 | 0.04 | 0.92 | 0.31 | −0.04 | 0.46 | 57.76 |
| 6A(%) | −0.04 | 0.48 | −0.03 | 0.88 | −0.01 | 0.96 | 40.36 |
| CCT(μm) | −0.13 | 0.11 | −0.26 | 0.32 | 0.03 | 0.04 | 509.31 |
CD cell density, CV coefficient of variation, 6A hexagonality, CCT central corneal thickness, IOP intraocular pressure
aMixed lineal model
bY = ß1 × IOP + ß2 × time + ß3 × IOP × time + Y-intercept